Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb trial in of FG001 in aggressive brain cancer as a standalone treatment compared to Gliolan (5-ALA)

Next Previous
Trial Profile

A Phase IIb trial in of FG001 in aggressive brain cancer as a standalone treatment compared to Gliolan (5-ALA)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 27 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FG 001 (Primary) ; Aminolevulinic acid
  • Indications Glioblastoma; Glioma
  • Focus Therapeutic Use
  • Sponsors FluoGuide

Most Recent Events

  • 29 Nov 2023 According to a FluoGuide media release, Primary endpoint has been met. (Sensitivity, defined as the relative number of patients where FG001 lights up the cancer, as confirmed by histopathology)
  • 13 Nov 2023 According to a FluoGuide media release, status changed from active, no longer recruiting to completed.
  • 13 Nov 2023 Topline results (n=12) presented in the FluoGuide Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top